Download PDF
Frauenheilkunde up2date 2008; 2(4): 327-346
DOI: 10.1055/s-2008-1076941
Allgemeine Gynäkologie und gynäkologische Onkologie

© Georg Thieme Verlag KG Stuttgart ˙ New York

Gestationsbedingte Trophoblasterkrankungen

F. Thiel, L.-C. Horn, S. Jud, M. W. Beckmann, J. Einenkel
Further Information

Publication History

Publication Date:
11 September 2008 (online)

Also available at
    Permissions and Reprints All articles of this category

Kernaussagen

Die gestationsbedingten Trophoblasterkrankungen (GTD) sind eine klinisch und morphologisch sehr heterogene Gruppe von pathologischen Veränderungen, die charakterisiert ist durch eine Fehldifferenzierung und/oder Proliferation von Trophoblastgewebe. Das Spektrum reicht von Befunden ohne Krankheitswert über benigne Erkrankungen bis hin zu sehr aggressiven Neoplasien. Als wichtigste Risikofaktoren gelten das mütterliche Alter und vorausgegangene hydatidiforme Molenschwangerschaften; die elterliche Blutgruppenkonstellation und die Einnahme oraler Kontrazeptiva stellen weitere Risikofaktoren dar.

Symptomatisch äußern sich GTD mit den klassischen Zeichen einer physiologischen Frühschwangerschaft sowie häufig durch vaginale Blutungen, Anämie oder Druck bzw. Schmerzen im Unterbauch.

Die Prognose von gestationellen trophoblastären Neoplasien ist sehr gut. Alle Patientinnen mit einer Low-Risk-Erkrankung können mit einer Heilung rechnen. Das Überleben für High-Risk-Patientinnen beträgt derzeit 86 %. Das Gesamtüberleben ist ca. 98 %. Trotzdem bleiben viele Fragen im Bereich dieser seltenen Erkrankungen offen.

Literatur

  • 1 Soper J T, Mutch D G, Schink J C. American College of Obstetricians and Gynecologists. Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53.  Gynecol Oncol. 2004;  93 575-585
    CrossrefGoogle Scholar
  • 2 Altieri A, Franceschi S, Ferlay J et al. Epidemiology and aetiology of gestational trophoblastic diseases.  Lancet Oncol. 2003;  4 670-678
    CrossrefGoogle Scholar
  • 3 Berkowitz R S, Im S S, Bernstein M R et al. Gestational trophoblastic disease. Subsequent pregnancy outcome, including repeat molar pregnancy.  J Reprod Med. 1998;  43 81-86
    Google Scholar
  • 4 Parazzini F, Mangili G, La Vecchia C et al. Risk factors for gestational trophoblastic disease: a separate analysis of complete and partial hydatidiform moles.  Obstet Gynecol. 1991;  78 1039-1045
    Google Scholar
  • 5 Palmer J R, Driscoll S G, Rosenberg L et al. Oral contraceptive use and risk of gestational trophoblastic tumors.  J Natl Cancer Inst. 1999;  91 635-640
    CrossrefGoogle Scholar
  • 6 Costa H L, Doyle P. Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia – a systematic review.  Gynecol Oncol. 2006;  100 579-585
    CrossrefGoogle Scholar
  • 7 Norman R J, Green-Thompson R W, Jialal I et al. Hyperthyroidism in gestational trophoblastic neoplasia.  Clin Endocrinol (Oxf). 1981;  15 395-401
    CrossrefGoogle Scholar
  • 8 Kohorn E I. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment.  Int J Gynecol Cancer. 2001;  11 73-77
    PubMedGoogle Scholar
  • 9 Dhillon T, Palmieri C, Sebire N J et al. Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia.  J Reprod Med. 2006;  51 879-887
    Google Scholar
  • 10 Ngan H Y, Odicino F, Maisonneuve P et al. Gestational trophoblastic neoplasia. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer.  Int J Gynaecol Obstet. 2006;  95 Suppl 1 S193-S203
    CrossrefGoogle Scholar
  • 11 Shih I M, Kurman R J. The pathology of intermediate trophoblastic tumors and tumor-like lesions.  Int J Gynecol Pathol. 2001;  20 31-47
    CrossrefGoogle Scholar
  • 12 Baergen R N, Rutgers J L. Trophoblastic lesions of the placental site.  Gen Diagn Pathol. 1997;  143 143-158
    Google Scholar
  • 13 Vassilakos P, Riotton G, Kajii T. Hydatidiform mole: two entities. A morphologic and cytogenetic study with some clinical consideration.  Am J Obstet Gynecol. 1977;  127 167-70
    CrossrefGoogle Scholar
  • 14 Genest D R. Partial hydatidiform mole: clinicopathological features, differential diagnosis, ploidy and molecular studies, and gold standards for diagnosis.  Int J Gynecol Pathol. 2001;  20 315-322
    Google Scholar
  • 15 Seckl M J, Fisher R A, Salerno G et al. Choriocarcinoma and partial hydatidiform moles.  Lancet. 2000;  356 36-39
    CrossrefGoogle Scholar
  • 16 van Trommel N E, Massuger L F, Span P N et al. Early identification of treatment resistance in GTN.  Lancet Oncol. 2007;  8 866-867
    CrossrefGoogle Scholar
  • 17 Pezeshki M, Hancock B W, Silcocks P et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease.  Gynecol Oncol. 2004;  95 423-429
    CrossrefPubMedGoogle Scholar
  • 18 Vogel M, Horn L C. Gestational trophoblastic disease, villous gestational trophoblastic disease.  Pathologe. 2004;  25 269-279
    Google Scholar
  • 19 Fisher R A, Hodges M D, Newlands E S. Familial recurrent hydatidiform mole: a review.  J Reprod Med. 2004;  49 595-601
    Google Scholar
  • 20 Hodges M D, Rees H C, Seckl M J et al. Genetic refinement and physical mapping of a biparental complete hydatidiform mole locus on chromosome 19 q13.4.  J Med Genet. 2003;  40 95
    CrossrefGoogle Scholar
  • 21 Shih I M. Gestational trophoblastic neoplasia-pathogenesis and potential therapeutic targets.  Lancet Oncol. 2007;  8 642-650
    CrossrefPubMedGoogle Scholar
  • 22 Shih I M, Kurman R J. Molecular basis of gestational trophoblastic diseases.  Curr Mol Med. 2002;  2 1-12
    Google Scholar
  • 23 Mao T L, Kurman R J, Huang C C et al. Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis.  Am J Surg Pathol. 2007;  31 1726-1732
    CrossrefGoogle Scholar
  • 24 Mazur M T. Metastatic gestational choriocarcinoma. Unusual pathologic variant following therapy.  Cancer. 1989;  63 1370-1377
    CrossrefGoogle Scholar
  • 25 Ngan S, Seckl M J. Gestational trophoblastic neoplasia management: an update.  Curr Opin Oncol. 2007;  19 486-491
    CrossrefGoogle Scholar
  • 26 Kohorn E I. Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance?.  Gynecol Oncol. 2002;  85 36-39
    CrossrefGoogle Scholar
  • 27 McNeish I A, Strickland S, Holden L et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.  J Clin Oncol. 2002;  20 1838-1844
    CrossrefPubMedGoogle Scholar
  • 28 Rustin G J, Newlands E S, Lutz J M et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors.  J Clin Oncol. 1996;  14 2769-2773
    Google Scholar
  • 29 Seckl M J, Newlands E S. Treatment of gestational trophoblastic disease.  Gen Diagn Pathol. 1997;  143 159-171
    Google Scholar
  • 30 Newlands E S, Mulholland P J, Holden L et al. Etoposide and cisplatin / etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA / cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.  J Clin Oncol. 2000;  18 854-859
    Google Scholar
  • 31 Mao Y, Wan X, Lv W et al. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin / etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.  Int J Gynaecol Obstet. 2007;  98 44-47
    CrossrefGoogle Scholar
  • 32 Wang J, Short D, Sebire N J et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel / cisplatin alternating with paclitaxel / etoposide (TP / TE).  Ann Oncol May 2.
    Google Scholar
  • 33 Piura B, Rabinovich A, Meirovitz M et al. Placental site trophoblastic tumor: report of four cases and review of literature.  Int J Gynecol Cancer. 2007;  17 258-262
    CrossrefGoogle Scholar
  • 34 Kurman R J. The morphology, biology, and pathology of intermediate trophoblast: a look back to the present.  Hum Pathol. 1991;  22 847-855
    CrossrefGoogle Scholar
  • 35 Behtash N, Karimi Zarchi M. Placental site trophoblastic tumor.  J Cancer Res Clin Oncol. 2008;  134 1-6
    Google Scholar
  • 36 Young R H, Scully R E, McCluskey R T. A distinctive glomerular lesion complicating placental site trophoblastic tumor: report of two cases.  Hum Pathol. 1985;  16 35-42
    CrossrefGoogle Scholar
  • 37 Nagelberg S B, Rosen S W. Clinical and laboratory investigation of a virilized woman with placental-site trophoblastic tumor.  Obstet Gynecol. 1985;  65 527-534
    Google Scholar
  • 38 Machtinger R, Gotlieb W H, Korach J et al. Placental site trophoblastic tumor: outcome of five cases including fertility preserving management.  Gynecol Oncol. 2005;  96 56-61
    CrossrefGoogle Scholar
  • 39 Papadopoulos A J, Foskett M, Seckl M J et al. Twenty-five years' clinical experience with placental site trophoblastic tumors.  J Reprod Med. 2002;  47 460-464
    Google Scholar
  • 40 Swisher E, Drescher C W. Metastatic placental site trophoblastic tumor: long-term remission in a patient treated with EMA / CO chemotherapy.  Gynecol Oncol. 1998;  68 62-65
    CrossrefGoogle Scholar
  • 41 Mitchell H, Seckl M J. Discrepancies between commercially available immunoassays in the detection of tumour-derived hCG.  Mol Cell Endocrinol. 2007;  260–262 310-313
    Google Scholar

Dr. med. F. Thiel

Frauenklinik · Universitätsklinikum Erlangen

Universitätsstr. 21–23

91054 Erlangen

Email: falk.thiel@uk-erlangen.de